Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy.

Int J Womens Health · 2015 · PMC4294649 · PMID 25610001

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

failed to reach statistical significanceP =0.056so close (0.05 < p ≤ 0.1)

There was a trend towards improvement in overall survival for patients treated with eribulin (15.9 versus 14.5 months), with a favorable HR of 0.88 (95% CI 0.77–1.01); however this failed to reach statistical significance ( P =0.056).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.